Background Stip (1).png

Catch Cancer Before

It Starts

Colon Cancer Early Detection has a 91% Survival Rate Within the First Five Years

Background Stip (Dark Blue).png
Green Tick (1).png
Green Tick (1).png
Green Tick (1).png

Quick Procedure

       

A safe diagnostic

                         

Low manufacturing cost

The liquid biopsy market is estimated to reach

$3.8 billion by 2023

Growth Chart.png

Early Detection

Applied Biotech is developing a liquid biopsy test to catch cancer early which is a cornerstone of the UK's NHS Long Term Plan

Background Stip syringe.png

Opportunity

Superb opportunity to benefit from a unique cancer detection agent via a blood-based detection agent (liquid biopsy).

 

The solutions (TEVIPLEX and INNOPLEX) provide earlier cancer detection, this facilitates tumour therapeutic response determination and enable minimal residual disease monitoring for solid tumours.

 

The aim is to offer the latest technology screening and diagnostic tests that give standardised results, saving time and money, and to affirm our position as a key player in the clinical diagnostics market worldwide.

 

TEVIPLEX

The first technology TEVIPLEX is an innovative blood-based test to be used as a clinically applicable tool for diagnostic laboratories. The tool is a microfluidic chip that incorporates identifiable species of magnetic beads to capture small tumour particles that are shed by cancer cells (tumour-derived extracellular vesicles, TEVs).

 

The TEVs can be identified by incorporating the second technology INNOPLEX.

 

With the first TEVIPLEX prototype and pilot studies, Applied Biotech will be able to establish collaboration with key players within the early diagnosis field namely in a healthcare landscape that is familiar with such technologies.

 

Such collaborations will be vital to expand TEVIPLEX’s clinical studies and will enable potential technological partnering with other established liquid biopsy approaches.

INNOPLEX

The second technology INNOPLEX is able to detect multiple signatures sensitively and accurately in one test, using minimal material.

 

INNOPLEX has already been validated on solid tissue biopsies within breast cancer tissue where it was shown to achieve >95% concordance with the current, more laborious, standard of care.

With these new technologies diagnosis of cancer can be reduced from 22 days using biopsy/tissue, to 3 days with TEVIPLEX and INNOPLEX. All achieved with a lower manufacturing cost than the incumbent system.

Background Stip Computer.png
 

Expansion

Phase 1

Launch of the instrument and first chips for the detection of the 5 main cancers (Breast, Colon, Lung, Pancreas and Ovarian)

 

Phase 2

Applied Biotech aims to develop chips for the detection of other tumours as well as integrating other technologies within the profiling modules enabling users to study the entire biological spectrum of the isolated cancer particles (DNA, RNA, microRNA and protein). This second Phase is expected towards the end of 2024

Lab Experiment
 
Background Stip (Dark Blue).png

Debt & Equity Investment

Applied Biotech Limited is seeking a £3,000,000 Equity and a £3,000,000 Debt investment, totalling £6,000,000. The Equity investments are split into 3 tickets show below:

 

  • 1st investment of £1 million will receive 5% equity

  • 2nd investment of £1 million will receive 4% equity

  • 3rd investment of £1 million will receive 3% equity

 

This investment will enable them to carry out further research and development of their innovative liquid biopsy product, INNOPLEX and TEVIPLEX.

This will also finance the commercialisation of this ground-breaking product.

Portfolio Pic.png
Liquid Biopsy sale.png

Return on Investment

Equity Return

£3,000,000 will secure 12 % equity in Applied Biotech Limited. 

Debt Return

The £3,000,000 debt investment is over 3 years, giving a 24% return on investment.

Investment Structure

Equity ROI

Investment

Shareholding Offer 

10 Year IRR

£3,000,000

12%

57.9%

Debt ROI

Investment

Interest Rate

Monthly Repayments

Total Interest Paid %

Total Interest Paid

£3,000,000

8%

36

24%

£720,000

Frequently asked questions

How does liquid biopsy work?


Tumours release a variety of biomolecules into the bloodstream that can be collected via a bloodstream that can be collected via a blood test.




What are the most common causes of cancer death?


  • Lung (1.76 million deaths)
  • Colorectal (862 000 deaths)
  • Stomach (783 000 deaths)
  • Liver (782 000 deaths)
  • Breast (627 000 deaths)




What are the reasons for the high death rate of cancer?


  • Delayed diagnosis and lack of screening solutions (worse survival)
  • Lack of precise tumour classification
  • Lack of therapeutic monitoring




How does TEVIPLEX work?


Early detection of cancer via a microfluidic approach to capture tumour particles on multiplex, magnetic beads for detection and profiling. The beads capture small tumour particles that are shed by cancer cells (tumour-derived extracellular vesicles, TEVs)




How does INNOPLEX work?


Tumour digital classification to guide precision medicine. This is able to detect multiple signatures sensitively and accurately in one test, using minimal material.




What is the benefit of the technology?


  • Early detection
  • More sensitive and detailed to enable patient classification for effective treatment
  • Repeatable (blood sampling instead of tissue sampling)
  • Can detect TEVs before the tumour forms
  • Efficient with minimal, low quality sample with maximum information from multiple biomarkers
  • Cost and time savings via an objective numerical result, no pathologist objective interpretation required
  • Faster results via less process steps




What is a TEV?


Tumour-derived extracellular vesicles.




Can INNOPLEX work on solid tissue biopsies?


Innoplex has already been validated on solid tissue biopsies within breast cancer tissue where it was shown to achieve >95% concordance with the current, more laborious standard of care.




Who are the key partners and collaborators?


  • Leeds University
  • Sagentia




How much quicker is the diagnosis by TEVIPLEX and INNOPLEX?


Tumour is profiled within 3 days.




What are the cancers to be detected in the first stage of development?


Breast, Colon, Lung, Pancreas and Ovarian.




Does the company hold any patents?


Applied Biotech have 10 patents either published, filed or under development.




What is the value of the cancer diagnostic market?


US$ 144 billion in 2018 expected to grow to US$ 248 billion in 2026.




What countries have the highest rates of cancer?


Age-standardised rate per 100,000

  1. Australia 468.0
  2. New Zealand 438.1
  3. Ireland 373.7
  4. Hungary 368.1
  5. USA 352.2
  6. Belgium 345.8
  7. France (metropolitan) 344.1
  8. Denmark 340.4
  9. Norway 337.8
  10. Netherlands 334.1




How much does an Innoplex all in one profile test cost?


Just £51.




Is tissue biopsy considered surgery?


During a surgical biopsy a surgeon makes an incision in the skin to access the suspicious area of cells. Examples of surgical biopsy procedures include surgery to remove a breast lump for a possible breast cancer diagnosis and surgery to remove a lymph node for a possible lymphoma diagnosis.




What are the potential exit strategies?


  • Merger with a bigger company such as the major partner ThermoFisher or similar company.
  • Initial Public Offering (IPO).
  • Sell to an interested third party.




How much does TEVIPLEX + INNOPLEX cost for pan cancer early detection from blood?


£100 GBP





 

Need more information?

Disclaimer

This communication is directed only at professional investors and not for distribution to the general public. The information contained herewith has been issued by Applied Biotech Limited and therefore ELC cannot take any responsibility for the completeness of the information. No representation or warranty express or implied is made or given by on behalf of the company as to the accuracy and completeness or fairness of the information or opinions contained in this document and no responsibility or liability is accepted for such information or opinions or any errors, omissions, misstatements negligent or otherwise.